$XBI $135.65 +4%
Pipeline Updates
$BTAI -3% Ph 1b/2 data. source
$AVXL +6% Interim DSMB recommendation to continue ph 2b/3 study. source
$CTIC -2% Completes rolling NDA for pacritinib for myelofibrosis. source
$SNDX +7% Orphan Drug granted. source
$EXEL +3% EU approval of Cabometyx + Opdivo. source
Finance Updates
$ CTIC -2% Offering. source
Comments